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Over the past several years, genomic technologies have evolved
that enable the simultaneous analysis of the expression of hun-
dreds to thousands of genes. This capability has completely
changed the types of questions and the quality of information
that can be queried by biomedical scientists. The functional sta-
tus of a living cell can be characterized at the molecular level by
its gene expression patterns. Cells belonging to different tissues
and organs, cells in various developmental stages, cells in differ-
ent metabolic states, cells under the influence of specific chemi-
cals (whether natural or synthetic, endogenous or exogenous),
cells within a diseased tissue or tumor—all may differ by their
gene expression patterns at any given point in time. 
Of the various applications of genomic technologies, toxicology
is one of the most pragmatic in terms of its role in the safety assess-
ment of new therapeutic candidates. The analysis and evaluation of
gene and protein expression changes that modulate toxic responses
has been named toxicogenomics and toxicoproteomics, respec-
tively. These emerging disciplines promise to revolutionize the
field of toxicology by aiding and supplementing our mechanistic
understanding of how drug treatments in animals and humans
induce toxic insults in one or more tissues or organs. With the pos-
sible exception of very rapid cell death, it is believed that gene
expression changes underlie all drug-induced toxic events. The
question is will analysis of drug-induced gene expression changes
lead to a better understanding of the mechanism of toxicity? And if
so, can investigators use this knowledge to design a safer drug with-
out compromising the drug’s beneficial (therapeutic) effects? Will
genomic analysis lead to the identification of useful biomarkers of
toxicity, i.e., a biological signal that can be measured in patients
that will accurately report or, better yet, predict the onset of drug-
induced toxicity? Will genomic analysis lead to gene expression or
protein expression patterns that become the “signature” of toxic
potential for that particular drug? If the answer is “yes,” then can
genomic patterns become useful screens applied in the early drug
discovery stages, leading to less toxic “lead candidates” that enter
drug development? These questions and others are being intensely
and actively investigated by nearly every major pharmaceutical and
biotechnology company as well as by the U.S. Food and Drug
Administration (FDA), the National Institute of Environmental
Health Sciences, and numerous academic laboratories.
Over the past several years, a number of forums involving the
pharmaceutical and biotechnology industries, regulatory agencies, and
academia have been organized to address some of these challenges. In
mid-1999 the Health and Environmental Sciences Institute (HESI)
of the International Life Sciences Institute (ILSI) (http://hesi.ilsi.org/)
formed a project committee to develop a collaborative scientific pro-
gram to identify and address some of the key issues arising from the
emerging application of toxicogenomics to drug safety risk assess-
ment. The investigational studies conducted and reported by this
consortium (Hamadeh et al. 2002; ILSI/HESI 2003) created a path
for several other forums focused on this and related topics. An active
HESI consortium now exists for the search, characterization, and vali-
dation of biomarkers of drug-induced toxicity. Immediate goals
include the design and conduct of studies that will identify early
predictive biomarkers of nephrotoxicity,
cardiotoxicity, and testicular toxicity.
It is now apparent that one major
application of toxicogenomics in drug
development is the identification and char-
acterization of early predictive biomarkers
of toxicity. More sensitive and specific biomarkers will contribute
not only to the understanding of the mechnisms involved in drug-
induced toxic responses but also to improving human risk assess-
ment that is fundamental to the drug approval process by the
FDA or other regulatory agencies. Many of the conventional bio-
markers used in preclinical drug safety studies are either insensi-
tive, nonspecific, or they appear late in the pathogenesis of the
lesion and, as such, qualify only as reporters or indicators of toxic-
ity. Other criticisms of conventional biomarkers include their
noninvasive accessibility, their limited species specificity, and their
relevance to human risk. Genomic-derived biomarkers have the
potential of appearing early in the pathogenesis of the lesion, pos-
sibly serving as predictors as opposed to indicators of toxicity
(Goodsaid 2003; Guerreiro et al. 2003). In addition, genomic
technologies have the potential of expanding accessible biomarkers
across test species in toxicology studies. One of the major goals is
to discover biomarkers that bridge preclinical and clinical studies.
A variety of recent forums have focused on the issue of
genomic data submission to support human risk assessment. The
FDA and PhRMA (Pharmaceutical Research and Manufacturers
of America) have sponsored workshops focused on the generation
of guidelines for genomic data submission. The inaugural meet-
ing, held spring 2002, created the framework for several follow-
up meetings on this topic. The FDA perspective is that genomic
data will enrich new drug applications, and the agency has
encouraged sponsors to submit genomic data in drug submissions
under a “safe harbor” provision. The majority of sponsors are
concerned that the science of genomics is still developing and
that the FDA is not prepared to review or interpret genomics
data. The fear is that submission of genomics data will result in
significant differences in data interpretation, resulting in many
questions that will delay FDA approvals. The Drug Information
Association (DIA) in collaboration with the FDA, PhRMA, the
Biotechnology Industry Organization (BIO), and the companies
represented by the Pharmacogenomics Working Group (PWG)
has scheduled a workshop 13–14 November 2003 that will dis-
cuss and debate the draft FDA guidelines titled “The Genomic
Data Submission (GDS) Proposal” (http://www.diahome.org).
Within the context of pharmaceutical drug development, the
ultimate payoff for toxicogenomics and toxicoproteomics can be
enormous. However, we are not ready for “prime time.” Many
challenges must be met to ensure scientific valid and appropriate
incorporation of these technologies into product development,
product evaluation, product regulation, and ultimately, medical
practice. From a regulatory viewpoint, several critical issues will
likely affect the level of scientific scrutiny of genomic-derived data.
Key factors include the stage or stages of drug development at
which these technologies are applied. The FDA emphasized that
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the level and rigor of scientific scrutiny of data will depend
on when in drug development these methods are applied and how
the resultant data intend to be used. The outcome of the
DIA–FDA–PhRMA–BIO–PWG workshop in November should
help clarify many impending issues and pave the way for new tech-
nological applications that can improve the risk assessment process.
A tremendous effort of everyone will be needed to move
rationally in the direction of achieving scientific credibility, fol-
lowed by regulatory and scientific consensus of how and when to
apply genomic data to drug development and the approval of
new medicines. The payoffs include a better understanding of
human diseases, safer and more effective drugs to treat diseases,
and more efficient and quicker development time for producing
and marketing new therapeutic agents.
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Editorial
Genomic technologies have the potential of expanding accessible biomarkers
across test species in toxicology studies. One of the major goals is to discover
biomarkers that bridge preclinical and clinical studies.